Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bionano Genomics Inc BNGO

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform... see more

NDAQ:BNGO - Post Discussion

Bionano Genomics Inc > only product on the market today employing the OGM system
View:
Post by OTCLegenda on Aug 23, 2022 10:33am

only product on the market today employing the OGM system

a strong product that could play an integral role in genome analysis and generate a healthy profit from the increasing footprint of the genetic medicines and research market. In a research note issued on July 18, Francois Brisebois at Oppenheimer gave Bionano Genomics stock a target price of $12 with an Outperform rating.
Comment by Legarsdunord on May 18, 2023 3:30pm
A year later and it's under a buck. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities